#3

Rec'd PCT/PTO 26 SEP 2001

Kevin L. Waugh
Name of Attorney or Agent

Signature of Attorney or Agent

P&G Case CM2003F

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Showell et al.:

Serial No. 09/889,254

Confirmation No. Not Yet Assigned

Filed July 13, 2001

For: DE

DETERGENT TABLETS COMPRISING A PECTATE LYASE

COMPLETION OF FILING REQUIREMENTS

Box Missing Parts

Commissioner for Patents

Washington, D.C. 20231

Dear Sir:

This paper is being filed in response to the Notification of Missing Requirements mailed August 23, 2001. A copy is enclosed for your convenience. Applicant respectfully asserts that no sequence listing is required in the present application and the request is made in error.

Applicant respectfully requests that the requirement be withdrawn.

Respectfully submitted,

IZ -- I -- I

Ke√in L. Waugh

Attorney for Applicant(s)

Registration No. 47,206

(513) 627-7386

September 24, 2001 K:/KLW/Cases/CM2003/CM2003FRespFormLet

Customer Number: 27752


1

Case Docket No. CM2003F

Box <u>PCT</u> COMMISSIONER FOR PATENTS Washington, D.C. 20231

Rec'd PCT/PTO 26 SEP 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on September 24, 2001.



Dear Sir:

Transmitted herewith is a RESPONSE TO NOTICE OF MISSING

REQUIREMENTS for the patent application:

Inventor(s): Showell et al.

Serial No.: 09/889,254

Group Art Unit: Not Yet Assigned

Date Filed: July 13, 2001

Examiner: Not Yet Assigned

Title: DETERGENT TABLETS COMPRISING A PECTATE LYASE

- 1. [X] No additional fee is known to be required.
- 2. [] The fee has been calculated as shown below:

					OTHER	THAN A
•	(Col. 1)		(Col. 2)	(Col. 3)	SMALL ENTITY	
	CLAIMS					
	REMAINING		HIGHEST NO.			
	AFTER	i	PREVIOUSLY	PRESENT		
	AMENDMENT		PAID FOR	EXTRA*	RATE	FEE
TOTAL	*	MINUS	**	=	x \$18 =	\$
INDEP.	*	MINUS	***	=	x \$80 =	\$
FIRST PRE	+ \$270 =	\$				
		·			TOTAL	\$

- 3. [] The Commissioner is hereby petitioned under 37 CFR §1.136(a) to grant any extension of time needed for timely response to the Office Action dated in the above-identified application to preserve pendency of said application. The processing fee under 37 CFR §1.17 has been determined as follows: \$ for a month extension of time.
- 4. The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 16-2480. A duplicate copy of this sheet is attached.
 - a. [x] Any patent application processing fees under 37 CFR §1.16.
 - b. [x] Any patent application processing fees under 37 CFR §1.17.
- 5. The Commissioner is hereby authorized to make any additional copies of this sheet needed to accomplish the purposes provided for herein and to charge any fee for such copies to Deposit Account No. 16-2480.

Kevin L. Waugh

Attorney for Applicant(s) Registration No. 47,206

Tel. No. (513) 627-7386

September 24, 2001

K:/KLW/Cases/CM2003/trCM2003FrespFormLet

Customer Number: 27752

THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

6. If box 3a or 3c is checked, a translation of the Annexes MUST be submitted no later than the time period set above or the Annexes will be cancelled. A processing fee will be required if submitted later than 20 or 30 months from the priority date. 7. The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d))

CALL:

(703) 308-4216, for Rules interpretation, (703) 308-4212, for CRF submission help,

Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	FIRST NAMED APPLICANT		
09/889254	SHOWELL	M	CM2003F	
09/669254	.•	INTERNATIONAL APPLICATION NO.		
THE PROCTER & GAMBLE COI	MPANY	PCT/US99/00800		
PATENT DIVISION MIAMI VALLEY LABORATORIES	5	I.A. FILING DA	ATE PRIORITY DATE	
P.O. BOX 538707 CINCINNATI, OH 45253 8707		14 JAN 9	AN 99	
CINCINNATI, OH 45255 6767	•		93 AUG 2001	

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

The application fails to comply with the requirements of 37 CFR 1.821-1.825.
my: "Aliestica door not contain a "Sequence Listing" as a senarate part of the
disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
A copy of the "Sequence Listing" in computer readable format has not been submitted as
required by 37 CFR 1 821(c).
A copy of the "Sequence Listing" in computer readable form has been submitted. The
content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw
Sequence Listing."
The computer readable form that has been filed with this application has been found to be
damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
The paper copy or compact disc of the "Sequence Listing" is not the same as the
computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
Other:
PPLICANT MUST PROVIDE:
An initial or substitute computer readable form (CRF) of the "Sequence Listing."
An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an
amendment directing its entry into the specification.
A statement that the contents of the paper or compact disc and the computer readable form
are the same and, where applicable, include no new matter, as required by 37 CFR
1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
OR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE